SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Abbott India informs about clarification on news article

06 Mar 2025 Evaluate

Pursuant to Regulation 30(11) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed that the Company clarified the following news article published in the mainstream media on March 5, 2025: News headline: ‘Pediatricians’ summit sponsored by infant formula maker in violation of law’. Clarification: ‘Abbott India Limited’ was erroneously mentioned in the news article. The corrected version of the article states ‘Abbott India’, which refers to Abbott in India. Further, the business referred to in the news article (Nutrition) does not belong to the listed entity, Abbott India.

The above information is a part of company’s filings submitted to BSE.

Abbott India Share Price

25797.15 -65.00 (-0.25%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×